Source: FierceBiotech Stryker has acquired OrthoSpace, developers of a therapy for severely torn rotator cuffs, in a deal worth up to $220 million, split evenly between upfront cash and future milestone payments. The Israel-based OrthoSpace has developed a biodegradable balloon spacer that fits between the shoulder’s scapula and acromonion bones,…...
Sun Pharmaceutical Industries Inc. Announces Plans to Present 19 Data Abstracts on ILUMYA™ for Moderate-to-Severe Plaque Psoriasis at American Academy of Dermatology 2019 Annual Meeting
Source: PR Newswire PRINCETON, N.J., Feb. 27, 2019 /PRNewswire/ -- Sun Pharmaceutical Industries Inc., USA (SPII) today announced that it plans to present 19 abstracts featuring data on ILUMYA™ (tildrakizumab-asmn), a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic or phototherapy, at the 77th Annual Meeting of the American Academy…...
FDA approves Medtronic device for sealing off deeper, smaller brain aneurysms
Source: FierceBiotech Medtronic has received approval of an expanded indication from the FDA for its Pipeline Flex embolization device, for patients with smaller aneurysms found deeper in the brain. The system was previously approved for endovascular treatment with large or giant, wide-necked intracranial aneurysms, located in the internal carotid artery…...
Anthem moves up launch of its PBM to second quarter of 2019
Source: FierceHealthcare Anthem is planning to begin moving members into its new PBM, IngenioRx, in the second quarter of 2019, bumping up the projected launch from 2020. Anthem announced the change as part of its fourth-quarter earnings (PDF), saying it moved up IngenioRx’s launch because Cigna closed its acquisition of Anthem’s current pharmacy benefit manager,…...
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Source: BusinessWire Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders…...
Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TRKA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2B Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019
Source: Sienna Biopharmaceuticals WESTLAKE VILLAGE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced top-line results from a Phase 2b study of SNA-120 (pegcantratinib), the Company’s lead drug candidate developed using its proprietary Topical by Design™ platform. This Phase 2b study, in mild-to-moderate…...
Telehealth firm 98point6 nets $50M in round led by Goldman Sachs
Source: FierceBiotech 98point6, a digital health company that makes primary care doctors available to patients over cellphone messages, raised $50 million in a new financing round led by Goldman Sachs. Its platform uses artificial intelligence to automate the tasks that don’t require direct physician interaction, such as gathering information on…...
Sanofi, Regeneron score positive Dupixent data in sinusitis as they await key FDA asthma verdict
Source: FiercePharma As the FDA gets set to decide whether Sanofi and Regeneron’s atopic dermatitis drug, Dupixent, can make a bid for asthma sales, the companies are churning out data in a variety of other conditions in hopes of boosting the product even more. The latest? Positive numbers from two phase 3 trials…...
UnitedHealth buys Genoa Healthcare, adding more than 400 pharmacies to its PBM
Source: FierceHealthcare With new competitors closing in, UnitedHealth is bolstering its defenses by purchasing Genoa Healthcare, the fifth-largest pharmacy chain in the country with 435 locations. Genoa—which also offers telepsychiatry services and medication management for behavioral health patients—will be absorbed by UnitedHealth’s pharmacy benefit manager OptumRx. According to its website,…...
Alexion snaps up another biotech, paying $1.2B for Syntimmune
Source: FierceBiotech Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune. The takeover gives Alexion control of SYNT001—a neonatal Fc receptor (FcRn) inhibitor in phase 1b/2a trials for patients with warm autoimmune hemolytic anemia (WAIHA) and pemphigus vulgaris (PV)…...